Impact of diabetes mellitus on kidney transplant recipients in Spain

Nephrology Dialysis Transplantation

Volumn 19, Issue SUPPL. 3, 2004, Pages

  González Posada, Jose Manuel ^a   Hernández, Domingo ^a   Bayés Genís, Beatriz ^b   García Perez, Javier ^c   Rivero Sanchez, Manuel ^d  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

Diabetes mellitus; Kidney transplantation; Survival

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADULT; AGE; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEMODIALYSIS; HUMAN; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; RISK FACTOR; SEX DIFFERENCE; SPAIN;

ADULT; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; FEMALE; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPAIN; SURVIVAL RATE;

EID: 3242697089     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh1017     Document Type: Article

References (20)

1. Hariharan S, Johnson CP, Breshnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612
2. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: Increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59: 732-737
3. Revanur KR, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 2001; 15: 89-94
4. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation. Kidney Int 2002; 62: 1440-1446
5. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 1-8
6. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735-1743
7. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy - the concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167-181
8. Gill JS, Pereira BJG. Death in the first year after transplantation: implications for patients on the transplant waiting list. Transplantation 2003; 75: 113-117
9. Bhalla V, Nast CC, Stollenweek N et al. Recurrent and de novo diabetic nephropathy in renal allografts. Trasnsplantation 2003; 75: 66-71
10. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25: 592
11. Weir MR, FinK JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34: 1-13
12. Hjelmesaeth J, Jenssen T, Hartmann A. Diagnosing PTDM. Transplantation 2002; 74: 579
13. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039
14. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183
15. Besse T, Grabensee B, Klein B et al. Multicenter randomised trial comparing tacrolimus (FK-506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436-443
16. Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging. Transplant Study Group. Transplantation 2000; 69: 875-880
17. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173 194
18. de Vries APJ, Bakker SJL, van Son WJ et al. Insulin resistance as putative cause of chronic renal transplant dysfunction. Am J Kidney Dis 2003; 41: 859-867
19. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ranipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342; 145-153
20. Woodward RS, Schnitzler MA, Baty J et al. Incidence and cost of new onset diabetes mellitus among US wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590-598